職名 講師
氏名 ひらいとしのり
平井利典
生年月 1986.08
所属 部局 附属病院
学科・専攻 薬剤部
講座  
教育研究分野 臨床薬剤学
TEL  
FAX  
E-mail hirai-toshinori@med. (末尾に mie-u.ac.jp を補ってください)
個人のホームページ https://researchmap.jp/t.hirai
学歴 明治薬科大学 学士課程 (2005年04月01日~2009年03月31日) 卒業・修了
明治薬科大学 博士課程・博士後期課程 (2012年04月01日~2016年09月30日) 卒業・修了
学位 2016.09 博士(薬学) 明治薬科大学
所属学会 日本臨床薬理学会 日本医療薬学会 日本TDM学会 日本腎臓病薬物療法学会 日本薬学会
社会活動  
職歴 2009.04~2017.05 東京女子医科大学病院 薬剤師
2017.06~2018.03 東京女子医科大学東医療センター 薬剤師
2018.04~2020.11 東京女子医科大学東医療センター 薬剤師 主任
2020.12~ 三重大学医学部附属病院 薬剤部 講師
学術(芸術)賞 第40回日本臨床薬理学会学術総会 優秀演題賞,血管新生阻害薬投与患者におけるRAS阻害薬の抗尿蛋白効果と降圧コントロールの関係,2019.12
専門分野 臨床薬理学・薬物動態学・医療薬学
現在の研究課題 医薬品適正使用を志向した臨床薬理学的研究
担当科目 看護病態学III
主な業績等 Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid. 2016 Biological & pharmaceutical bulletin 39 1013-21
A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function. 2017 European journal of clinical pharmacology 73 1491-1497
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients. 2018 British journal of clinical pharmacology 84 2260-2269
Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study. 2018 Journal of pharmaceutical health care and sciences 4 30-
Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments. 2018 Journal of clinical pharmacy and therapeutics 43 829-835
Correction to: Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment. 2019 European journal of clinical pharmacology 75 867-
Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. 2019 Cancer chemotherapy and pharmacology 84 195-202
Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment. 2019 European journal of clinical pharmacology 75 859-866
Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study. 2020 Biological & pharmaceutical bulletin 43 782-787
Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database. 2020 International journal of clinical pharmacology and therapeutics 58 543-549
Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: A retrospective observational descriptive study. 2020 Journal of clinical pharmacy and therapeutics 45 666-673
Geriatric Patients Are at a High Risk of Hypokalemia Associated with Yokukansan Preparation: A Retrospective Cohort Study. 2020 Biological & pharmaceutical bulletin 43 1742-1748
Relationship between Recurrent Falls and Medication Use during Acute-Care Hospitalization: A Retrospective Descriptive Study. 2020 Biological & pharmaceutical bulletin 42 1192-1198
Serum Digoxin Concentrations and Outcomes in Patients with Heart Failure and Atrial Fibrillation: A Single-Center Observational Study 2020 Japanese Journal of Clinical Pharmacology and Therapeutics 51 57-64
A meta-analysis of observational studies on anticholinergic burdenand fracture risk: evaluation of conventional burden scales. 2021 Journal of Pharmceutical Health Care and Sciences
Acute Kidney Injury Impacts on Hypokalemia Associated with Yokukansan Preparation: A Retrospective Observational Study. 2021 Biological and Pharmaceutical Bulletin 44 118-124
Effect of high-dose sulfamethoxazole/trimethoprim and glucocorticoid use on hyperkalemic event: A retrospective observational study. 2021 Journal of Infection and Chemotherapy
Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: a secondary analysis using a retrospective observational data 2021 Basic & Clinical Pharmacology & Toxicology
Safety profiles of new xanthine oxidase inhibitors: A post-marketing study. 2021 International journal of clinical pharmacology and therapeutics 59 372-377